An ad-hoc group of infectious disease doctors and health researchers on Tuesday held a public meeting to review recent ...

Study: Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023.

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

The Food and Drug Administration on Wednesday approved Arexvy, the world's first respiratory syncytial virus (RSV) vaccine — a scientific breakthrough 60 years in the making.

In 2023, the FDA approved three RSV vaccines for older adults. Studies have shown these vaccines to be effective, with the Pfizer, GSK, and Moderna vaccines preventing RSV pneumonia and bronchitis ...

According to data collected from preliminary studies, Pfizer's vaccine was 82% effective at protecting newborns, within the first three months of life, from severe RSV illness.

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab ...

U.S. regulators on Monday, Aug. 21, 2023, approved the first RSV vaccine for pregnant women so their babies will be born with protection against the scary respiratory infection.

Currently, there is no vaccine that exists for RSV, and infants younger than 6 months old are too young to receive most vaccines recommended by the Centers for Disease Control and Prevention.

The US FDA approved an RSV vaccine called Arexvy. How effective is it, when will it be available, and who can take it? CNN Medical Analyst Dr. Leana Wen explains.

Pfizer’s RSV vaccine for pregnant people The FDA announced Wednesday it has agreed to review Pfizer’s vaccine candidate, RSVpreF, for approval and set an action date for August 2023.

The FDA will decide whether or not to approve an RSV vaccine by August 2023. After decades of research, a first-of-its kind vaccine designed to protect newborns against RSV, or respiratory ...